OBJECTIVE: Research has implicated dysfunction of glutamatergic neurotransmission in
the pathophysiology of schizophrenia. This review evaluates evidence from preclinical and …

Numerous clinical studies demonstrate that subanesthetic doses of dissociative anesthetics,
which are noncompetitive antagonists at the NMDA receptor, replicate in normal subjects …

Background: Medical morbidity and mortality rates remain elevated in schizophrenia patients
compared with the general population, in part due to potentially reversible medical risk …

Background In a preliminary dose-finding study, D-cycloserine, a partial agonist at the
glycine modulatory site of the glutamatergicN-methyl-D-aspartate (NMDA) receptor, improved …

One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet
limited data exist on its prevalence in US patients with schizophrenia. METHODS: Using …

OBJECTIVE: The goal of this 5-year naturalistic study of patients treated with clozapine was
to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, …

Background Schizophrenia is characterized by small reductions in cortical gray matter
volume, particularly in the temporal and prefrontal cortices. The question of whether cortical …

Objective The authors' goal was to study the relationship between smoking status and clinical
characteristics in schizophrenic patients. Method Seventy-eight schizophrenic outpatients …

OBJECTIVE: Standardized mortality rates are elevated in schizophrenia compared to the
general population. The incidence of coronary heart disease (CHD) and the relative …

Persons diagnosed with schizophrenia have higher morbidity and mortality rates from
cardiovascular disease, yet often have limited access to appropriate primary care screening or …